A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL.
Yang JJ, et al. Among authors: wang z, wang bc.
Br J Cancer. 2017 Feb 28;116(5):568-574. doi: 10.1038/bjc.2016.456. Epub 2017 Jan 19.
Br J Cancer. 2017.
PMID: 28103612
Free PMC article.
Clinical Trial.